ProMIS Neurosciences (PMN) Share-based Compensation (2021 - 2026)
ProMIS Neurosciences' (PMN) quarterly Share-based Compensation came in at $203171.0 in Q4 2025, down 67.4% YoY from $623189.0 in Q4 2024, and up 3.06% on a QoQ basis from $197147.0 in Q3 2025.
ProMIS Neurosciences (PMN) Share-based Compensation (2021 - 2026) Analysis & Trends
ProMIS Neurosciences (PMN) has 5 years of Share-based Compensation data on file, last reported at $203171.0 in Q4 2025.
- Quarterly Share-based Compensation fell 67.4% year-over-year to $203171.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $857628.0 (up 3.85% YoY) and the FY2025 annual result came in at $857628.0, down 46.18% from the prior year.
- Share-based Compensation rose to $203171.0 in Q4 2025, from $197147.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $623189.0 in Q4 2024 to a low of $4841.0 in Q4 2023.
- A 5-year average of $155987.0 and a median of $126264.0 in 2021 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2023 — Share-based Compensation plunged 94.63% — and 2024, when it soared 12773.15%.
- Tracing PMN's Share-based Compensation over 5 years: stood at $118149.0 in 2021, then retreated by 23.7% to $90150.0 in 2022, then sank by 94.63% to $4841.0 in 2023, then soared by 12773.15% to $623189.0 in 2024, then slumped by 67.4% to $203171.0 in 2025.
- The last three Share-based Compensation figures came in at $203171.0 (Q4 2025), $197147.0 (Q3 2025), and $212015.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | ProMIS Neurosciences | 132.34 Mn | 78.87 Mn | - | 408,895.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 408,895.00 |
| Jun 30, 2026 | 408,895.00 |
| Mar 31, 2026 | 189,425.00 |
| Mar 31, 2026 | 189,425.00 |
| Dec 31, 2025 | 203,171.00 |
| Dec 31, 2025 | 203,171.00 |
| Sep 30, 2025 | 197,147.00 |
| Sep 30, 2025 | 197,147.00 |
| Jun 30, 2025 | 212,015.00 |
| Jun 30, 2025 | 212,015.00 |
| Mar 31, 2025 | 245,295.00 |
| Mar 31, 2025 | 245,295.00 |
| Dec 31, 2024 | 623,189.00 |
| Dec 31, 2024 | 623,189.00 |
| Sep 30, 2024 | 121,036.00 |
| Sep 30, 2024 | 121,036.00 |
| Jun 30, 2024 | 17,999.00 |
| Jun 30, 2024 | 17,999.00 |
| Mar 31, 2024 | 63,584.00 |
| Mar 31, 2024 | 63,584.00 |